Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease

Use of monoamine oxidase inhibitors in chronic neurodegeneration

(2017) Peter Riederer et al.   Expert Opinion on Drug Metabolism & Toxicology

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis

(2017) Carlo Cattaneo et al.   Journal of Parkinsons Disease

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations

(2017) Anthony H. V. Schapira et al.   JAMA Neurology

Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease

(2016) Félix Javier Jiménez-Jiménez et al.   Expert Opinion on Drug Metabolism & Toxicology

Safinamide: First Global Approval

(2015) Emma D. Deeks   DRUGS

Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

(2015) Thomas Müller   DRUGS

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

(2015) P. Barone et al.   EUROPEAN JOURNAL OF NEUROLOGY

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

(2015) Rajesh Pahwa et al.   MOVEMENT DISORDERS

Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis

(2015) Carlo Cattaneo et al.   Journal of Parkinsons Disease

Mavoglurant as a treatment for Parkinson’s disease

(2014) Dmitry Petrov et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease

(2014) Rupam Borgohain et al.   MOVEMENT DISORDERS

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

(2013) Rupam Borgohain et al.   MOVEMENT DISORDERS

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

(2013) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys

(2013) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers

(2013) Chiara Leuratti et al.   PHARMACOLOGY

Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor

(2013) Samantha Podurgiel et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects

(2012) Sonja Krösser et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Rasagiline

(2012) Sheridan M. Hoy et al.   DRUGS

The PRIPS study: screening battery for subjects at risk for Parkinson's disease

(2012) D. Berg et al.   EUROPEAN JOURNAL OF NEUROLOGY

Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease

(2012) Thomas Müller et al.   JOURNAL OF NEURAL TRANSMISSION

Dopamine, Corticostriatal Connectivity, and Intertemporal Choice

(2012) A. S. Kayser et al.   JOURNAL OF NEUROSCIENCE

Amantadine: The journey from fighting flu to treating Parkinson disease

(2012) G. Hubsher et al.   NEUROLOGY

Drug therapy in patients with Parkinson’s disease

(2012) Thomas Müller   Translational Neurodegeneration

Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease

(2011) Jan-Philipp Bach et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers

(2011) Andrea Francesco Daniele Di Stefano et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Tolcapone Effects on Gating, Working Memory, and Mood Interact with the Synonymous Catechol-O-methyltransferase rs4818C/G Polymorphism

(2009) Panos Roussos et al.   BIOLOGICAL PSYCHIATRY

What do clinical trials tell us about treating patients?

(2009) William J. Weiner   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

There Is No Parkinson Disease

(2008) William J. Weiner   ARCHIVES OF NEUROLOGY